Fig. 5.

Plasma oxylipin quantification. (a) Heatmap showing PUFAs, CYP-, LOX-, COX-derived oxylipins, and sEH activity readout in lean patients (N = 9), patients with obesity (N = 50) and patients with obesity and T2DM (N = 25). (b) 10 most significantly changing (FDR<0.05) and sEH activity ratios (separated by a dashed line) determined by Kruskal–Wallis test. (c) LOX- , CYP- and COX-derived oxylipins in lean patients (N = 9), patients with obesity (N = 50) and patients with obesity and T2DM (N = 25). Heatmaps (a and b) were generated on normalized data (log10 transformed) and clustered using Ward. Significance was tested by Kruskal–Wallis test followed by Dunn's multiple comparison (c).